Table 2.
Demographic, clinical, laboratory values and discharge characteristics in discharged and dead patients with brain hemorrhages and COVID-19 positive.
| Predictors | Discharged | Died | P value |
|---|---|---|---|
| Age-years, mean (SD) | 67.16 (16.2) | 66.87 (15.15) | 0.958 |
| Female sex, n (%) | 6 (31.6) | 8 (50) | 0.268 |
| White | 4 (21.1) | 0 (0) | 0.049a |
| African-American | 9 (47.4) | 4 (25) | |
| Hispanic | 5 (26.3) | 9 (56.3) | |
| Other | 1 (5.3) | 3 (18.8) | |
| BMI | 25.38 (4.94) | 29.34 (7.15) | 0.083a |
| Severe COVID-19 on admission, n (%) | 2 (10.5) | 9 (56.3) | 0.004a |
| Inpatient, n (%) | 4 (21.1) | 7 (43.8) | 0.150 |
| Emergency, n (%) | 15 (78.9) | 9 (56.3) | |
| Surgical management, n (%) | 3 (15.8) | 1 (6.3) | 0.377 |
| Fever, n (%) | 2 (11.1) | 4 (26.7) | 0.249 |
| Hypoxemia, n (%) | 5 (27.8) | 6 (40) | 0.458 |
| Systolic blood pressure (mmHg), median (IQR) | 140 (124−154) | 121 (104−133) | 0.073a |
| Diastolic blood pressure (mmHg), median (IQR) | 69.5 (65−88) | 65 (53−72) | 0.126 |
| Hypertension, n (%) | 14 (73.7) | 11 (68.8) | 0.784 |
| Diabetes, n (%) | 6 (31.6) | 4 (25) | 0.668 |
| Congestive heart failure, n (%) | 1 (5.3) | 5 (31.3) | 0.042a |
| Myocardial infarction, n (%) | 0 (0) | 2 (12.5) | 0.112 |
| Chronic pulmonary disease, n (%) | 0 (0) | 0 (0) | – |
| Any malignancy, n (%) | 1 (5.3) | 4 (25) | 0.096a |
| WBC >10,800 per mm3, n (%) | 4 (22.2) | 8 (50) | 0.126 |
| Lymphocytes <1000 per mm3, n (%) | 10 (55.6) | 10 (62.5) | 0.681 |
| Platelets <100,000 per mm3, n (%) | 1 (5.6) | 2 (12.5) | 0.476 |
| ALT>40 U/L, n (%) | 5 (29.4) | 9 (60) | 0.082a |
| AST>40 U/L, n (%) | 5 (29.4) | 9 (64.3) | 0.052a |
| PTT > 38.9 s, n (%) | 0 (0) | 6 (46.2) | 0.002a |
| INR > 1.2, n (%) | 2 (12.5) | 8 (61.5) | 0.006a |
| D-dimer >2 ng/mL, n (%) | 8 (61.5) | 9 (81.8) | 0.276 |
| Creatinine >1.33 μmol/L | 4 (22.2) | 7 (46.7) | 0.138 |
| BUN >20 mg/dL | 10 (55.6) | 10 (66.7) | 0.515 |
| Traumatic hemorrhage, n (%) | 10 (52.6) | 3 (18.8) | 0.039a |
| Spontaneous, n (%) | 9 (47.4) | 13 (81.3) | |
| Hx of Anticoagulants, n (%) | 4 (21.1) | 3 (18.8) | 0.865 |
| Hx of Antiplatelets, n (%) | 5 (26.3) | 0 (0) | 0.027a |
| Hemorrhagic subtypes | |||
| SDH, n (%) | 11 (57.9) | 6 (37.5) | 0.606 |
| SAH, n (%) | 1 (5.3) | 1 (6.3) | |
| MCH, n (%) | 2 (10.5) | 5 (31.3) | |
| MFH, n (%) | 2 (10.5) | 2 (12.5) | |
| Focal ICH, n (%) | 3(15.8) | 2 (12.5) |
a
Included in the multivariate analysis.